Evidence map›Paper›PMID 29663358›Full record

ArticleInternational journal of cancer2018

A case-control study of HIV infection and cancer in the era of antiretroviral therapy in Rwanda.

Tharcisse Mpunga, Ariana Znaor, F Regis Uwizeye, Aline Uwase, Cyprien Munyanshongore, Silvia Franceschi, Gary M Clifford

Open access · hybridAbstract read
In one paragraph

Article in International journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Tharcisse MpungaButaro Cancer Centre of Excellence, Ministry of Health, Butaro, Rwanda.
Ariana ZnaorInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0002-5849-4782
F Regis UwizeyePartners In Health/Inshuti Mu Buzima, Kigali, Rwanda.
Aline UwaseButaro Cancer Centre of Excellence, Ministry of Health, Butaro, Rwanda.
Cyprien MunyanshongoreUniversity of Rwanda, School of Public Health, Kigali, Rwanda.
Silvia FranceschiCancer Epidemiology Unit, CRO Aviano National Cancer Institute IRCCS, Aviano, Italy.
Gary M CliffordInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-7534-333X
Centre international de recherche sur le cancer · FRMinistry of Health · RWCentro di Riferimento Oncologico · ITUniversity of Global Health Equity · RWUniversity of Rwanda · RW

Funding

World Health Organization 001
6 · The paper itself

Abstract

The aim of this study was to assess the association between HIV infection and cancer risk in Rwanda approximately a decade after the introduction of antiretroviral therapy (cART). All persons seeking cancer care at Butaro Cancer Center of Excellence (BCCOE) in Rwanda from 2012 to 2016 were routinely screened for HIV, prior to being confirmed with or without cancer (cases and controls, respectively). Cases were coded according to ICD-O-3 and converted to ICD10. Associations between individual cancer types and HIV were estimated using adjusted unconditional logistic regression. 2,656 cases and 1,196 controls differed by gender (80.3% vs. 70.8% female), age (mean 45.5 vs. 37.7 years), place of residence and proportion of diagnoses made by histopathology (87.5% vs. 67.4%). After adjustment for these variables, HIV was significantly associated with Kaposi Sarcoma (n = 60; OR = 110.3, 95%CI 46.8-259.6), non-Hodgkin lymphoma (NHL) (n = 265; OR = 2.5, 1.4-4.6), Hodgkin lymphoma (HL) (n = 76; OR = 5.2, 2.3-11.6) and cancers of the cervix (n = 560; OR = 5.9, 3.8-9.2), vulva (n = 23; OR = 17.8, 6.3-50.1), penis (n = 29; OR = 8.3, 2.5-27.4) and eye (n = 17; OR = 4.7, 1.0-25.0). Associations varied by NHL/HL subtype, with that for NHL being limited to DLBCL (n = 56; OR = 6.6, 3.1-14.1), particularly plasmablastic lymphoma (n = 6, OR = 106, 12.1-921). No significant associations were seen with other commonly diagnosed cancers, including female breast cancer (n = 559), head and neck (n = 116) and colorectal cancer (n = 106). In conclusion, in the era of cART in Rwanda, HIV is associated with increased risk of a range of infection-related cancers, and accounts for an important fraction of cancers presenting to a referral hospital.

Indexed as

Antiretroviral Therapy, Highly ActiveAdolescentAdultAgedCase-Control StudiesFemaleFollow-Up StudiesHIVHIV InfectionsHodgkin DiseaseHumansIncidenceLymphoma, AIDS-RelatedMaleMiddle AgedPrognosiscancerepidemiologyHIV

Identifiers

PMID29663358
PMCPMC6099235
OpenAlexW2800741336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.